At a glance
- Originator Galderma
- Class Antineoplastics; Retinoids
- Mechanism of Action Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Oct 2005 Discontinued - Preclinical for Cancer in France (unspecified route)
- 04 Oct 2005 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 04 Oct 2005 Discontinued - Preclinical for Cancer in USA (unspecified route)